These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 280664)

  • 21. [Use of a herbal infusion of Origanum in hemophilia patients during tooth extraction].
    Klement AA; Fedorova ZD; Volkova SD; Egorova LV; Shul'kina NM
    Probl Gematol Pereliv Krovi; 1978 Jul; (7):25-8. PubMed ID: 353792
    [No Abstract]   [Full Text] [Related]  

  • 22. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.
    Nilsson IM; Hedner U; Holmberg L
    Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of microcrystalline collagen for hemostasis after oral surgery in a hemophiliac.
    Evans BE; Irving SP; Aledort LM
    J Oral Surg; 1979 Feb; 37(2):126-8. PubMed ID: 283205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tooth extraction under hypnosis in an hemophiliac].
    Dufour J; D'Auteuil P; Dionne P
    Rev Fr Odontostomatol; 1968; 15(7):955-60. PubMed ID: 4879181
    [No Abstract]   [Full Text] [Related]  

  • 25. [Problems in the dental treatment of a case of hemophilia A].
    Sakai M; Saito T; Ikeshima K; Kamata M; Yoshikawa T; Kaneko M; Kamioka H; Masujima J; Ikeda M; Sato H
    Tohoku Shika Daigaku Gakkai Shi; 1986 Mar; 13(1):37-43. PubMed ID: 2943645
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of the hemophilic oral surgery patient.
    Glogoff M; Baum SM; Sussman R; Stewart S; Stoopack JC
    J Oral Surg; 1972 Apr; 30(4):252-62. PubMed ID: 4536912
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
    Sultan Y; Brouet JC
    Nouv Presse Med; 1975 Oct; 4(36):2571-4. PubMed ID: 1081682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antihemophilic cryoprecipitate from fresh plasma and its use in hemophilia A].
    Brüster H; Glassner K; Riech PC
    Dtsch Med Wochenschr; 1967 Oct; 92(41):1859-66. PubMed ID: 6057144
    [No Abstract]   [Full Text] [Related]  

  • 30. Ineffectiveness of intramuscularly injected Factor 8 concentrate in two hemophilic patients.
    Pool JG; Welton J; Creger WP
    N Engl J Med; 1966 Sep; 275(10):547-8. PubMed ID: 5917950
    [No Abstract]   [Full Text] [Related]  

  • 31. Antihemophilic factor (AHF): plasma levels after administration of AHF preparations to hemophilic dogs.
    WAGNER RH; LANGDELL RD; RICHARDSON BA; FARRELL RA; BRINKHOUS KM
    Proc Soc Exp Biol Med; 1957 Oct; 96(1):152-5. PubMed ID: 13485042
    [No Abstract]   [Full Text] [Related]  

  • 32. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Cudzinowski L
    ASDC J Dent Child; 1979; 46(1):54-6. PubMed ID: 283081
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of epsilon aminocaproic acid as an adjunct to replacement therapy in hemophiliacs undergoing tooth extraction (part II).
    Evans BE
    N Y J Dent; 1981 Apr; 51(4):117-27. PubMed ID: 6784050
    [No Abstract]   [Full Text] [Related]  

  • 34. Report of a clinical trial of a Canadian preparation of antihemophilic factor.
    Magnin AA; Johnson SE
    Can Med Assoc J; 1979 Aug; 121(4):422-4, 427. PubMed ID: 466616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Safe and cost-conscious supply of factor-VIII-deficient Swiss hemophiliacs with AHF preparations].
    Stampfli K
    Ther Umsch; 1977 Oct; 34(10):717-24. PubMed ID: 918896
    [No Abstract]   [Full Text] [Related]  

  • 36. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors.
    Brinkhous KM; Shanbrom E; Roberts HR; Webster WP; Fekete L; Wagner RH
    JAMA; 1968 Aug; 205(9):613-7. PubMed ID: 5695099
    [No Abstract]   [Full Text] [Related]  

  • 37. [The dosage of antihemophilic globulin, or antihemophilic plasma as well as Cohn's fraction I in factor VIII deficiency].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):363-8. PubMed ID: 4195283
    [No Abstract]   [Full Text] [Related]  

  • 38. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third-party reimbursement for pharmacist instruction about antihemophilic factor.
    Fudge RP; Vlasses PH
    Am J Hosp Pharm; 1977 Aug; 34(8):831-4. PubMed ID: 900134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevention of hemorrhage in patients with hemophilia].
    Pliushch OP; Rutberg RA; Zakhrova NS; Shefter LI
    Probl Gematol Pereliv Krovi; 1976 Jan; 21(1):11-3. PubMed ID: 1273055
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.